HTX-L01-008 / Hopewell Therap - LARVOL DELTA

Hopewell Therapeutics to Present Data Highlighting Novel Tissue Targeting Lipid Nanoparticles at the American Society of Gene and Cell Therapy 27th Annual Meeting (PRNewswire) - "Hopewell Therapeutics...announced that the Company will present preclinical data demonstrating progression of its pulmonary, oncology and vaccine programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting being held this week in Baltimore, MD, as well as virtually....In addition, Hopewell's lead liver-targeting LNP has been used to deliver mRNA encoding novel bispecific T-cell engagers (BiTES), which have demonstrated deep and sustained B-cell depletion in a non-human primate model, as well as reduction in tumor volume in a hepatocellular carcinoma mouse model."

Preclinical • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor